Rallybio Corporation
RLYBRallybio is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of life-transforming therapies for patients with severe and rare diseases.
Table of contents
Earnings
Next report
Aug 6, 2026 (In 1 week)Competitors
By market cap
By revenue growth
Profile
Rallybio is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of life-transforming therapies for patients with severe and rare diseases. The company leverages deep expertise in rare disease research to advance a pipeline of candidates targeting complement dysregulation and iron overload disorders. Following a significant merger agreement, the company is expanding its focus to include T-cell engager therapeutics for autoimmune diseases.
Rallybio is a clinical-stage developer transitioning into a broader immunology-focused entity through strategic M&A and specialized rare disease expertise.
Questions, answered.
- What is Rallybio Corporation's market cap?
- Rallybio Corporation (RLYB) has a market capitalization of $86.6M and trades on NASDAQ.
- Who are Rallybio Corporation's competitors?
- Rallybio Corporation's key competitors include Amgen, Fulcrum Therapeutics, Inc. Common Stock, Larimar Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Rallybio Corporation partner with?
- Rallybio Corporation's notable partners include Recursion Pharmaceuticals, Inc., Exscientia Ventures I, Inc..
- What subsidiaries does Rallybio Corporation have?
- Rallybio Corporation's subsidiaries include Candid, Farmington Merger Sub, Inc., Rallybio IPB, LLC.
- Where is Rallybio Corporation headquartered?
- Rallybio Corporation is headquartered in United States of America and employs approximately 30 people. It has been publicly traded since 2021.